Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as an adjunctive treatment for major depressive disorder (MDD). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback